Stage	Treatment options	5-year survival rates (%)*
0	Gastrectomy with lymphadenectomy	90
I	Distal subtotal gastrectomy (if the lesion is not in the fundus or at the cardioesophageal junction)†	58 to 78
	Proximal subtotal gastrectomy or total gastrectomy, both with distal esophagectomy (if the lesion involves the cardia)†
	Total gastrectomy (if the tumor involves the stomach diffusely or arises in the body of the stomach and extends to within 6 cm of the cardia or distal antrum)†
	Postoperative chemoradiation therapy in patients with node-positive (T1 N1) and muscle-invasive (T2 N0) disease
	Neoadjuvant chemoradiation therapy‡
II	Distal subtotal gastrectomy (if the lesion is not in the fundus or at the cardioesophageal junction)†	34
	Proximal subtotal gastrectomy or total gastrectomy (if the lesion involves the cardia)†
	Total gastrectomy (if the tumor involves the stomach diffusely or arises in the body of the stomach and extends to within 6 cm of the cardia)†
	Postoperative chemoradiation therapy
	Neoadjuvant chemoradiation therapy‡
III	Radical surgery. Curative resection procedures are confined to patients who at the time of surgical exploration do not have extensive nodal involvement.	8 to 20
	Postoperative chemoradiation therapy
	Neoadjuvant chemoradiation therapy‡
IV	Patients with no metastases (M0)	7
	Radical surgery if possible, followed by postoperative chemoradiation Neoadjuvant chemoradiation therapy‡
	Patients with distant metastases (M1)§
	Palliative chemotherapy with: fluorouracil, FAM, FAP, ECF, ELF, PELF, FAMTX, FUP
	Endoscopic laser therapy or endoluminal stent placement may be helpful in patients whose tumors have occluded the gastric inlet.
	Palliative radiation therapy may alleviate bleeding, pain, and obstruction.
	Palliative resection should be reserved for use in patients with continued bleeding or obstruction.